US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
- The 'real-life Martha' from Baby Reindeer bombarded Sir Keir Starmer with almost 300 emails, it has2024-05-21
Ancient Town Boosts Local Cultural Tourism in Mangshi City, SW China
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21Ningbo Holds Series of Activities to Enrich Night Life of Citizens, Tourists
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21Women Become Major Force in China's Tourism Consumption Market
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21Minnesota Uber and Lyft driver pay package beats deadline to win approval in Legislature
ST. PAUL, Minn. (AP) — A plan to boost pay for Uber and Lyft drivers in Minnesota that lawmakers bel2024-05-21More Young Chinese Enjoy Visiting Museums
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21
atest comment